Oral Cancer - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 70

Oral Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Oral Cancer - Pipeline Review, H1 2012', provides an overview of the Oral Cancer therapeutic pipeline. This report provides information on the therapeutic development for Oral Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Cancer . 'Oral Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Oral Cancer .
- A review of the Oral Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Oral Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Oral Cancer .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Oral Cancer pipeline depth and focus of Oral Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Oral Cancer Therapeutic Products under Development, Key Players in Oral Cancer Therapeutics, Oral Cancer Pipeline Overview, Oral Cancer Pipeline, Oral Cancer Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oral Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Oral Cancer
Oral Cancer Therapeutics under Development by Companies
Oral Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Oral Cancer Therapeutics – Products under Development by Companies
Oral Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Oral Cancer Therapeutics Development
CEL-SCI Corporation
NexMed, Inc.
Oral Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HPPH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tarceva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Advexin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actos - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Survivin-Derived Peptide Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-00299804 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panitumumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Palifermin + Cyclophosphamide + Etoposide + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lapatinib Ditosylate + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxotere + Cisplatin + 5-FU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erbitux + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Curcumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Nedaplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VTX-2337 + Cetuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Multikine + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZD6474 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Cancer Therapeutics – Drug Profile Updates
Oral Cancer Therapeutics – Discontinued Products
Oral Cancer Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Oral Cancer, H1 2012
Products under Development for Oral Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
CEL-SCI Corporation, H1 2012
NexMed, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Oral Cancer Therapeutics – Drug Profile Updates
Oral Cancer Therapeutics – Discontinued Products
Oral Cancer Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Oral Cancer, H1 2012
Products under Development for Oral Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Oral Cancer - Pipeline Review, H2 2012
• Oral Cavity (Mouth) Cancer - Pipeline Review, H2 2012
• Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2012
• Diabetic Macular Edema - Pipeline Review, H1 2013
• Alopecia - Pipeline Review, H1 2013
• Diphtheria - Pipeline Review, H1 2013
• Rotavirus Infections – Pipeline Review, H1 2013